New eye injection aims to slow genetic blindness
NCT ID NCT06461286
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medicine called PYC-001, given as an injection into the eye, for people with a genetic condition that damages the optic nerve (OPA1 optic atrophy). The main goal is to check if the treatment is safe and tolerable. About 18 adults will receive a single dose, and researchers will monitor for side effects and any changes in vision.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT OPTIC ATROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center for Eye Research Australia (CERA)
East Melbourne, Victoria, 3002, Australia
-
Save Sight Institute - Sydney Eye Hospital
Sydney, New South Wales, 2000, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.